This protocol addresses patients with advanced-stage nodal marginal zone lymphoma (NMZL) who have low tumour burden and are currently free of clinical symptoms. In this subset, the initial management approach differs from that used in symptomatic or high-burden presentations.
For eligible patients in this setting, active surveillance is a recognised first-line management option. The full protocol details the specific eligibility criteria, monitoring schedule, and the conditions that would prompt a change in course.
DOI: 10.1016/j.annonc.2019.10.010
In advanced-stage NMZL with low tumour burden and lack of clinical symptoms, a watch-and-wait strategy may be followed.
View source ↗